Offering was led by an initial investment from a premier healthcare-dedicated investor alongside multiple large existing shareholders
Alpha Cognition Inc., a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, announced the pricing of its oversubscribed underwritten public offering of 5,600,000 common shares (or pre-funded warrants in lieu thereof), at a public offering price of $6.25 per share. The gross proceeds of the offering are approximately $35.0 million, before deducting underwriting discounts, commissions, and estimated offering expenses. All securities in this offering were sold by the Company.
Health Technology Insights: Microsoft Healthcare Executive Kim Swafford Joins RAAPID Advisory Board
The Company plans to allocate the net proceeds for the acceleration of commercial launch, with an emphasis on sales expansion, marketing investment, enhancing payer coverage, and reimbursement infrastructure. These investments are designed to maximize near-term adoption while laying the foundation for long-term revenue growth and a sustainable commercial presence in the Alzheimer’s treatment landscape.
Health Technology Insights: ENHERTU Plus Pertuzumab Gets US Priority Review for HER2+ Breast Cancer
“The enthusiastic support from both existing and new healthcare investors underscores confidence in our vision and growth potential,” said Michael McFadden, Chief Executive Officer. “We believe the net proceeds from this offering will accelerate the commercialization of ZUNVEYL (Benzgalantamine), enabling us to capitalize on early commercial learnings and set the foundation for key initiatives that will drive long-term shareholder value.”
The Company has granted the underwriter a 30-day option to purchase up to an additional 840,000 common shares to cover over-allotments, if any, at the per share public offering price, less underwriting discounts and commissions.
Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for the offering.
The offering is expected to close on or about October 2, 2025, subject to the satisfaction of customary closing conditions.
The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-289792) filed with the Securities and Exchange Commission (“SEC”) on August 22, 2025, and declared effective by the SEC on August 29, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available for free on the SEC’s website at www.sec.gov. A final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC.
Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 24 September 2025
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
